Search
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Categories: Experimental Unapproved Treatments for COVID-19Sarconeos
go.drugbank.com/drugs/DB16457InvestigationalSarconeos is an activator of the MAS receptor.
Categories: Experimental Unapproved Treatments for COVID-19Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.
Categories: Experimental Unapproved Treatments for COVID-19STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Categories: Experimental Unapproved Treatments for COVID-19STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Categories: Experimental Unapproved Treatments for COVID-19Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers.